{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:23:04Z","timestamp":1764994984176,"version":"3.46.0"},"reference-count":40,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,12,5]]},"DOI":"10.1248\/bpb.b25-00433","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T22:07:04Z","timestamp":1764886024000},"page":"1876-1886","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic Reovirus-Induced Prostaglandin E2 Production in Human Tumor Cells"],"prefix":"10.1248","volume":"48","author":[{"given":"Ikuho","family":"Ishigami","sequence":"first","affiliation":[{"name":"Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka 565\u20130871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics, Faculty of Pharmacy, Kindai University, Osaka 577\u20138502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Ihara","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics, Faculty of Pharmacy, Kindai University, Osaka 577\u20138502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawase","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics, Faculty of Pharmacy, Kindai University, Osaka 577\u20138502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Mizuguchi","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka 565\u20130871, Japan"},{"name":"Laboratory of Functional Organoid for Drug Discovery, Center for Drug Discovery Resources Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka 567\u20130085, Japan"},{"name":"Global Center for Medical Engineering and Informatics, The University of Osaka, Osaka 565\u20130871, Japan"},{"name":"Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), The University of Osaka, Osaka 565\u20130871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1366-9662","authenticated-orcid":false,"given":"Fuminori","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka 565\u20130871, Japan"},{"name":"Laboratory of Biopharmaceutics, Faculty of Pharmacy, Kindai University, Osaka 577\u20138502, Japan"},{"name":"Pharmaceutical Research and Technology Institute, Kindai University, Osaka 577\u20138502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Lowenstein PR, Varela ML, Castro MG. The discrete charm of oncolytic viruses: Toward the finish line. <i>Cancer Cell<\/i>, <b>43<\/b>, 611\u2013618 (2025).","DOI":"10.1016\/j.ccell.2025.03.010"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. <i>Nat. Rev. Drug Discov.<\/i>, <b>14<\/b>, 642\u2013662 (2015).","DOI":"10.1038\/nrd4663"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. <i>Cytokine Growth Factor Rev.<\/i>, <b>21<\/b>, 91\u201398 (2010).","DOI":"10.1016\/j.cytogfr.2010.02.006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Maitra R, Ghalib MH, Goel S. Reovirus: a targeted therapeutic--progress and potential. <i>Mol. Cancer Res.<\/i>, <b>10<\/b>, 1514\u20131525 (2012).","DOI":"10.1158\/1541-7786.MCR-12-0157"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Zhao X, Chester C, Rajasekaran N, He Z, Kohrt HE. Strategic combinations: the future of oncolytic virotherapy with reovirus. <i>Mol. Cancer Ther.<\/i>, <b>15<\/b>, 767\u2013773 (2016).","DOI":"10.1158\/1535-7163.MCT-15-0695"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. <i>Nat. Rev. Cancer<\/i>, <b>18<\/b>, 419\u2013432 (2018).","DOI":"10.1038\/s41568-018-0009-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kiss M, Vande Walle L, Saavedra PHV, <i>et al<\/i>. IL1\u03b2 promotes immune suppression in the tumor microenvironment independent of the inflammasome and gasdermin D. <i>Cancer Immunol. Res.<\/i>, <b>9<\/b>, 309\u2013323 (2021).","DOI":"10.1158\/2326-6066.CIR-20-0431"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Nixon BG, Gao S, Wang X, Li MO. TGF\u03b2 control of immune responses in cancer: a holistic immuno-oncology perspective. <i>Nat. Rev. Immunol.<\/i>, <b>23<\/b>, 346\u2013362 (2023).","DOI":"10.1038\/s41577-022-00796-z"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Saraiva M, Vieira P, O\u2019Garra A. Biology and therapeutic potential of interleukin-10. <i>J. Exp. Med.<\/i>, <b>217<\/b>, e20190418 (2020).","DOI":"10.1084\/jem.20190418"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Lacher SB, D\u00f6rr J, de Almeida GP, <i>et al<\/i>. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8<sup>+<\/sup> T cells. <i>Nature<\/i>, <b>629<\/b>, 417\u2013425 (2024).","DOI":"10.1038\/s41586-024-07254-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Morotti M, Grimm AJ, Hope HC, <i>et al<\/i>. PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. <i>Nature<\/i>, <b>629<\/b>, 426\u2013434 (2024).","DOI":"10.1038\/s41586-024-07352-w"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, Mensurado S, Moeini A, Flanagan E, Bell CR, Chiang S-C, Chikkanna-Gowda CP, Rogers N, Silva-Santos B, Jaillon S, Mantovani A, Reis e Sousa C, Guerra N, Davis DM, Zelenay S. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. <i>Immunity<\/i>, <b>53<\/b>, 1215\u20131229.e8 (2020).","DOI":"10.1016\/j.immuni.2020.10.020"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) L\u00f3pez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. <i>Cancer Cell<\/i>, <b>32<\/b>, 135\u2013154 (2017).","DOI":"10.1016\/j.ccell.2017.06.009"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Xiang X, Poliakov A, Liu C, Liu Y, Deng Z, Wang J, Cheng Z, Shah SV, Wang G, Zhang L, Grizzle WE, Mobley J, Zhang H. Induction of myeloid-derived suppressor cells by tumor exosomes. <i>Int. J. Cancer<\/i>, <b>124<\/b>, 2621\u20132633 (2009).","DOI":"10.1002\/ijc.24249"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Obermajer N, Kalinski P. Generation of myeloid-derived suppressor cells using prostaglandin E2. <i>Transplant. Res.<\/i>, <b>1<\/b>, 15 (2012).","DOI":"10.1186\/2047-1440-1-15"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Boumelha J, de Castro A, Bah N, Cha H, de Carn\u00e9 Tr\u00e9cesson S, Rana S, Tomaschko M, Anastasiou P, Mugarza E, Moore C, Goldstone R, East P, Litchfield K, Lee S-H, Molina-Arcas M, Downward J. CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. <i>Cancer Res.<\/i>, <b>84<\/b>, 2231\u20132246 (2024).","DOI":"10.1158\/0008-5472.CAN-23-2627"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Lane Starr NM, Evans MD, Lee KE, Gern JE, Denlinger LC. Ensemble analysis identifies nasal 15-Keto-PGE2 as a predictor of recovery in experimental rhinovirus colds. <i>J. Infect. Dis.<\/i>, <b>224<\/b>, 839\u2013849 (2021).","DOI":"10.1093\/infdis\/jiab015"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ricke-Hoch M, Stelling E, Lasswitz L, <i>et al<\/i>. Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. <i>PLOS ONE<\/i>, <b>16<\/b>, e0255335 (2021).","DOI":"10.1371\/journal.pone.0255335"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Jordan PM, G\u00fcnther K, Nischang V, Ning Y, Deinhardt-Emmer S, Ehrhardt C, Werz O. Influenza A virus selectively elevates prostaglandin E2 formation in pro-resolving macrophages. <i>iScience<\/i>, <b>27<\/b>, 108775 (2024).","DOI":"10.1016\/j.isci.2023.108775"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Terasawa Y, Hotani T, Katayama Y, Tachibana M, Mizuguchi H, Sakurai F. Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing. <i>Cancer Gene Ther.<\/i>, <b>22<\/b>, 188\u2013197 (2015).","DOI":"10.1038\/cgt.2015.4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Katayama Y, Tachibana M, Kurisu N, Oya Y, Terasawa Y, Goda H, Kobiyama K, Ishii KJ, Akira S, Mizuguchi H, Sakurai F. Oncolytic reovirus inhibits immunosuppressive activity of myeloid-derived suppressor cells in a TLR3-dependent manner. <i>J. Immunol.<\/i>, <b>200<\/b>, 2987\u20132999 (2018).","DOI":"10.4049\/jimmunol.1700435"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Hotani T, Tachibana M, Mizuguchi H, Sakurai F. Reovirus double-stranded RNA genomes and polyI: C induce down-regulation of hypoxia-inducible factor 1\u03b1. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>460<\/b>, 1041\u20131046 (2015).","DOI":"10.1016\/j.bbrc.2015.03.147"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kasai T, Nakanishi T, Ohno Y, Shimada H, Nakamura Y, Arakawa H, Tamai I. Role of OATP2A1 in PGE2 secretion from human colorectal cancer cells <i>via<\/i> exocytosis in response to oxidative stress. <i>Exp. Cell Res.<\/i>, <b>341<\/b>, 123\u2013131 (2016).","DOI":"10.1016\/j.yexcr.2016.02.002"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Shimada H, Hashimoto R, Aoki A, Yamada S, Oba K, Kawase A, Nakanishi T, Iwaki M. The regulatory mechanism involved in the prostaglandin E2 disposition in carbon tetrachloride-induced liver injury. <i>Prostaglandins Leukot. Essent. Fatty Acids<\/i>, <b>155<\/b>, 102081 (2020).","DOI":"10.1016\/j.plefa.2020.102081"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Eguchi M, Hirata S, Ishigami I, Shuwari N, Ono R, Tachibana M, Tanuma M, Kasai A, Hashimoto H, Ogawara K, Mizuguchi H, Sakurai F. Pre-treatment of oncolytic reovirus improves tumor accumulation and intratumoral distribution of PEG-liposomes. <i>J. Control. Release<\/i>, <b>354<\/b>, 35\u201344 (2023).","DOI":"10.1016\/j.jconrel.2022.12.050"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Mohamed A, Konda P, Eaton HE, Gujar S, Smiley JR, Shmulevitz M. Closely related reovirus lab strains induce opposite expression of RIG-I\/IFN-dependent <i>versus<\/i> -independent host genes, <i>via<\/i> mechanisms of slow replication <i>versus<\/i> polymorphisms in dsRNA binding \u03c33 respectively. <i>PLoS Pathog.<\/i>, <b>16<\/b>, e1008803 (2020).","DOI":"10.1371\/journal.ppat.1008803"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, Hiiragi A, Dermody TS, Fujita T, Akira S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. <i>J. Exp. Med.<\/i>, <b>205<\/b>, 1601\u20131610 (2008).","DOI":"10.1084\/jem.20080091"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Katayama Y, Terasawa Y, Tachibana M, Mizuguchi H, Sakurai F. Proteolytic disassembly of viral outer capsid proteins is crucial for reovirus-mediated type-I interferon induction in both reovirus-susceptible and reovirus-refractory tumor cells. <i>BioMed Res. Int.<\/i>, <b>2015<\/b>, 468457 (2015).","DOI":"10.1155\/2015\/468457"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Molina-Holgado E, Ortiz S, Molina-Holgado F, Guaza C. Induction of COX-2 and PGE<sub>2<\/sub> biosynthesis by IL-1\u03b2 is mediated by PKC and mitogen-activated protein kinases in murine astrocytes. <i>Br. J. Pharmacol.<\/i>, <b>131<\/b>, 152\u2013159 (2000).","DOI":"10.1038\/sj.bjp.0703557"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Neeb L, Hellen P, Boehnke C, Hoffmann J, Schuh-Hofer S, Dirnagl U, Reuter U. IL-1\u03b2 stimulates COX-2 dependent PGE<sub>2<\/sub> synthesis and CGRP release in rat trigeminal ganglia cells. <i>PLOS ONE<\/i>, <b>6<\/b>, e17360 (2011).","DOI":"10.1371\/journal.pone.0017360"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Fukunaga M, Fujiwara Y, Fujibayashi M, Ochi S, Yokoyama K, Ando A, Hirano T, Ueda N, Kamada T. Signal transduction mechanism of interleukin 6 in cultured rat mesangial cells. <i>FEBS Lett.<\/i>, <b>285<\/b>, 265\u2013267 (1991).","DOI":"10.1016\/0014-5793(91)80813-I"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Alfajaro MM, Choi J-S, Kim D-S, Seo J-Y, Kim J-Y, Park J-G, Soliman M, Baek Y-B, Cho E-H, Kwon J, Kwon H-J, Park S-J, Lee WS, Kang M-I, Hosmillo M, Goodfellow I, Cho K-O. Activation of COX-2\/PGE <sub>2<\/sub> promotes sapovirus replication <i>via<\/i> the inhibition of nitric oxide production. <i>J. Virol.<\/i>, <b>91<\/b>, e01656\u201316 (2017).","DOI":"10.1128\/JVI.01656-16"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Rodr\u00edguez L-S, Barreto A, Franco MA, Angel J. Immunomodulators released during rotavirus infection of polarized caco-2 cells. <i>Viral Immunol.<\/i>, <b>22<\/b>, 163\u2013172 (2009).","DOI":"10.1089\/vim.2008.0110"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Sir\u00e9n J, Imaizumi T, Sarkar D, Pietil\u00e4 T, Noah DL, Lin R, Hiscott J, Krug RM, Fisher PB, Julkunen I, Matikainen S. Retinoic acid inducible gene-I and mda-5 are involved in influenza A virus-induced expression of antiviral cytokines. <i>Microbes Infect.<\/i>, <b>8<\/b>, 2013\u20132020 (2006).","DOI":"10.1016\/j.micinf.2006.02.028"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Broquet AH, Hirata Y, McAllister CS, Kagnoff MF. RIG-I\/MDA5\/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium. <i>J. Immunol.<\/i>, <b>186<\/b>, 1618\u20131626 (2011).","DOI":"10.4049\/jimmunol.1002862"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Francica BJ, Holtz A, Lopez J, Freund D, Chen A, Wang D, Powell D, Kipper F, Panigrahy D, Dubois RN, Whiting CC, Prasit P, Dubensky TW. Dual blockade of EP2 and EP4 signaling is required for optimal immune activation and antitumor activity against prostaglandin-expressing tumors. <i>Cancer Res. Commun.<\/i>, <b>3<\/b>, 1486\u20131500 (2023).","DOI":"10.1158\/2767-9764.CRC-23-0249"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Punyawatthananukool S, Matsuura R, Wongchang T, Katsurada N, Tsuruyama T, Tajima M, Enomoto Y, Kitamura T, Kawashima M, Toi M, Yamanoi K, Hamanishi J, Hisamori S, Obama K, Charoensawan V, Thumkeo D, Narumiya S. Prostaglandin E2-EP2\/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells. <i>Nat. Commun.<\/i>, <b>15<\/b>, 9464 (2024).","DOI":"10.1038\/s41467-024-53706-3"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Abramovitz M, Adam M, Boie Y, Carri\u00e8re M-C, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N, Metters KM. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. <i>Biochimica et Biophysica Acta (BBA)<\/i>, <b>1483<\/b>, 285\u2013293 (2000).","DOI":"10.1016\/S1388-1981(99)00164-X"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Bell CR, Pelly VS, Moeini A, Chiang S-C, Flanagan E, Bromley CP, Clark C, Earnshaw CH, Koufaki MA, Bonavita E, Zelenay S. Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations. <i>Nat. Commun.<\/i>, <b>13<\/b>, 2063 (2022).","DOI":"10.1038\/s41467-022-29606-9"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. <i>Clin. Immunol.<\/i>, <b>119<\/b>, 229\u2013240 (2006).","DOI":"10.1016\/j.clim.2006.01.016"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/12\/48_b25-00433\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:24:43Z","timestamp":1764991483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/12\/48_b25-00433\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00433","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"b25-00433"}}